Home › Acute Myeloid Leukemia › Maryland
Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Maryland
31 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Maryland.
Mga Lungsod sa Maryland
Opisyal na teksto ng pag-aaral (English)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- at 10 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Johns Hopkins University, Baltimore
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- at 1 pa
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Hopkins School of Medicine, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05436418Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
1 Day – 100 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT03854318A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- The Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitObservasyonal na pag-aaral
Edad 0 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Baltimore MD-UMGCCC, Baltimore
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Baltimore MD-UMGCCC, Baltimore
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Maryland/Greenebaum Cancer Center, Baltimore
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 3 hanggang 35 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT02390752Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Tania Jain, MD, Baltimore
Nagre-recruitPhase 1
6 Months – 80 Years · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT02203903Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05588154Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
1 Day – 120 Years · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05350748Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Maryland Medical Center (UMMC), Baltimore
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaral
1 Month – 120 Years · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT07019155CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT04050280Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Johns Hopkins School of Medicine, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Johns Hopkins University, Baltimore
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 25, 2025 · NCT05237258Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.